[
    [
        {
            "time": "2018-03-15",
            "original_text": "Lilly To Participate in Leerink Partners Global Healthcare Conference",
            "features": {
                "keywords": [
                    "Lilly",
                    "Leerink Partners",
                    "Global Healthcare Conference"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly To Participate in Leerink Partners Global Healthcare Conference",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-28",
            "original_text": "Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",
            "features": {
                "keywords": [
                    "Incyte",
                    "Q4",
                    "Earnings Miss",
                    "Revenues Beat"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-02-27",
            "original_text": "5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings",
            "features": {
                "keywords": [
                    "Drug",
                    "Biotech",
                    "Stocks",
                    "Beat Estimates",
                    "Q4 Earnings"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-14",
            "original_text": "Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Twitter",
                    "Freeport-McMoRan"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "technology",
                    "mining"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-26",
            "original_text": "Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down",
            "features": {
                "keywords": [
                    "Teva",
                    "Q4",
                    "Earnings Miss",
                    "View Weak",
                    "Shares Down"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride",
            "features": {
                "keywords": [
                    "Boehringer Ingelheim",
                    "Lilly",
                    "CAROLINA®",
                    "cardiovascular",
                    "Tradjenta®",
                    "non-inferiority",
                    "glimepiride"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]